CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 91 enrolled
Drug / intervention
Dalbavancin +1 moredrug
Likely dose
Dalbavancin 1500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03233438
NCT03233438Phase 4Completed
CompareCT.gov

Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections

Allergan·interventional·Posted Jul 28, 2017·Updated Jan 18, 2020

In Brief

A Phase 4 clinical trial evaluating Dalbavancin and Usual Care for Bacterial Infections and Acute Bacterial Skin and Skin Structure Infection. Completed, enrolled 91 participants across 1 site.

Detailed Summary

The purpose of this study is to assess the effect of a new critical pathway (use of guideline-based patient identification criteria and for those who meet these criteria, use of dalbavancin) compared to usual care for the treatment of ABSSI (Acute Bacterial Skin and Skin Structure Infections)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBacterial Infections, Acute Bacterial Skin and Skin Structure Infection
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedJul 28, 2017
Enrollment StartJul 24, 2017
Primary CompletionOct 30, 2018
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 8.9 years ago

Interventions

Dalbavancindrug

Dalbavancin administered as a single IV dose of 1500 mg over 30 minutes.

Usual Caredrug

Usual care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.